(RTTNews) - Sensei Biotherapeutics, Inc. (SNSE) reported preliminary preclinical data from mouse and non-human primate studies of SNS-101, a monoclonal antibody targeting the immune checkpoint VISTA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results